Subscribe to RSS
Download PDF
DOI: 10.1055/s-0044-1790542
The Effect of Perioperative Cimetidine on the Outcomes of Stage 2 Melanoma
Authors
Abstract
Objectives
The use of immunotherapies in the treatment of melanoma has significantly improved the survival of patients with advanced disease. Historically, histamine has been implicated in the pathogenesis of several cancers. Cimetidine does play a role in modulating the immune system and was advocated as an immunotherapeutic agent since the 1970s. Cimetidine has been showing promise in conjunction with standard care in many cancers in vitro and in vivo. However, its effects in melanoma have not been explored yet. Our study was designed to determine if cimetidine taken in the perioperative period improves the disease-free survival (DFS) or overall survival in patients with the American Joint Committee on Cancer, seventh edition (AJCC 7) stage 2 melanoma.
Materials and Methods
We have reviewed all the patients with stage 2 melanoma in our center in a retrospective cohort to assess the difference in survival between patients who received H2 blockers in the perioperative period and those who did not.
Statistical Analysis and Results
Thirty-two patients were included in the analysis. Nine of 32 patients received H2 blockers in the perioperative period. All the patients were males except for one female in the control group (4.3%). The age in the analyzed population ranged between 51 and 92 years; the median age was 70 years (mean: 71; standard deviation: 10). The median overall survival of the patients who received H2 blockers was 112.7 months and it was 77.2 months for those who did not receive H2 blockers. There was no difference in DFS between the two groups (p = 0.5395), and there was no difference in the overall survival (p = 0.4770). The cumulative dose was strongly correlated with the overall survival in the patients who received H2 blockers (r = 0.8341, p = 0.0196).
Conclusion
Despite having a small treatment group, we were able to detect a strong correlation between the cumulative dose of H2 blockers received and the overall survival.
Publication History
Received: 13 August 2024
Accepted: 14 August 2024
Article published online:
16 September 2024
© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Conte S, Ghazawi FM, Le M. et al. Population-based study detailing cutaneous melanoma incidence and mortality trends in Canada. Front Med (Lausanne) 2022; 9: 830254
- 2 Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci (Basel) 2021; 9 (04) 63
- 3 Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev 2012; x (08) CD007814
- 4 Ali AH, Hale L, Yalamanchili B. et al. The effect of perioperative cimetidine administration on time to colorectal cancer recurrence. Am J Ther 2018; 25 (04) e405-e411
- 5 Fritz I, Wagner P, Bottai M. et al. Desloratadine and loratadine use associated with improved melanoma survival. Allergy 2020; 75 (08) 2096-2099
- 6 Eylemer Mocan E, Yekedüz E, Karataş G. et al. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients. Anticancer Drugs 2024; 35 (02) 190-194
- 7 Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol 2021; 14 (04) 101029